Gsk

• GSK is investing £400 million to relocate its research and development center to Cambridge, a move praised by Chancellor Rachel Reeves as a significant "vote of confidence" in the UK's life sciences sector. • The investment aims to strengthen the UK's position as a global hub for medical innovation and scientific research through the development of a state-of-the-art facility. • Simultaneously, global markets are facing volatility as a sell-off in AI stocks has pushed South Korea’s stock market to its lowest level in three months.

Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders“A vote of confidence in British business,” trumpeted Andy Burnham, seizing the political gift of GSK splashing out £400m on a shiny new research and development centre in Cambridge.For positive vibes, it definitely beats the early pharma news his predecessor as prime minister received. That was the painful tale of how AstraZeneca, frustrated by indecision in the Treasury, cancelled its intended £450m expansion of a vaccine plant in Speke in Liverpool. Continue reading...

Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D siteBusiness live – latest updatesThe British drugmaker GSK is to announce sweeping job cuts as part of a £1.9bn cost-cutting programme to pay for a £400m investment in UK life sciences over the next three years, including in a new research and development centre in Cambridge, as it looks to develop drugs more quickly under its new chief executive.The pharmaceuticals company announced on Tuesday it will move more than 1,000 of its scientists to its new site on the Cambridge biomedical campus. It will close its R&D site in Stevenage in Hertfordshire by 2029, while upgrading its R&D laboratories at nearby Ware and moving some employees there. Continue reading...

• Stock market futures are trending upward on Tuesday as a rebound in the technology sector drives positive momentum. • Investors are closely monitoring four specific stocks for potential movement: JetBlue (JBLU), GSK, Pfizer (PFE), and Novanta (NOVT). • Market sentiment is further bolstered by anticipation surrounding the upcoming SpaceX IPO, which is expected to attract significant investor interest.

British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading...

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drugGSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, steps up drug development efforts at the group.The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer. Continue reading...

• The FDA on March 13 expanded approval of GSK's Arexvy RSV vaccine to adults aged 18-49 at increased risk of lower respiratory tract disease. • Phase 3b trial data showed non-inferior immune response in younger adults compared to those 60+, targeting 21 million U.S. adults under 50 with conditions like diabetes or obesity. • RSV causes 17,000 hospitalizations, 277,000 emergency visits, and 2 million outpatient visits yearly in this group, highlighting need for broader protection amid rising cases.